Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall J Bateman

Showing results (31-40 of 391) with videos related to

Pageof 40
Sort By:
Journal of Proteome Research|September 9, 2008
Stable isotope labeling tandem mass spectrometry (SILT): integration with peptide identification and extension to data-dependent scansDonald L Elbert, Kwasi G Mawuenyega, Evan A Scott, et al.
Communications Biology|January 28, 2022
Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathwaysDonald L Elbert, Bruce W Patterson, Brendan P Lucey, et al.
Brain Communications|August 21, 2024
Multi-peptide characterization of plasma neurofilament light chain in preclinical and mild Alzheimer's diseaseJohn B Coulton, Yingxin He, Nicolas R Barthélemy, et al.
Annals of Neurology|February 15, 2020
Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal FluidNicolas R Barthélemy, Haiyan Liu, William Lu, et al.
Journal of Biomedical Materials Research. Part A|January 4, 2012
Exposure of the lysine in the gamma chain dodecapeptide of human fibrinogen is not enhanced by adsorption to poly(ethylene terephthalate) as measured by biotinylation and mass spectrometryVitaliy Ovod, Evan A Scott, Megan M Flake, et al.
Nature Medicine|June 27, 2006
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivoRandall J Bateman, Ling Y Munsell, John C Morris, et al.
Brain Communications|March 17, 2023
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's diseaseNicholas C Cullen, Shorena Janelidze, Erik Stomrud, et al.
Med (New York, N.Y.)|September 10, 2024
Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's diseaseYan Hu, Min Cho, Pallavi Sachdev, et al.
Alzheimer'S Research & Therapy|March 19, 2020
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identificationNicolas R Barthélemy, Randall J Bateman, Christophe Hirtz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersPetrice M Cogswell, Gregory M Preboske, Gregory Klein, et al.
Pageof 40

Showing results (31-40 of 391) with videos related to

Sort By:
Pageof 40
Journal of Proteome Research|September 9, 2008
Stable isotope labeling tandem mass spectrometry (SILT): integration with peptide identification and extension to data-dependent scansDonald L Elbert, Kwasi G Mawuenyega, Evan A Scott, et al.
Communications Biology|January 28, 2022
Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathwaysDonald L Elbert, Bruce W Patterson, Brendan P Lucey, et al.
Brain Communications|August 21, 2024
Multi-peptide characterization of plasma neurofilament light chain in preclinical and mild Alzheimer's diseaseJohn B Coulton, Yingxin He, Nicolas R Barthélemy, et al.
Annals of Neurology|February 15, 2020
Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal FluidNicolas R Barthélemy, Haiyan Liu, William Lu, et al.
Journal of Biomedical Materials Research. Part A|January 4, 2012
Exposure of the lysine in the gamma chain dodecapeptide of human fibrinogen is not enhanced by adsorption to poly(ethylene terephthalate) as measured by biotinylation and mass spectrometryVitaliy Ovod, Evan A Scott, Megan M Flake, et al.
Nature Medicine|June 27, 2006
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivoRandall J Bateman, Ling Y Munsell, John C Morris, et al.
Brain Communications|March 17, 2023
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's diseaseNicholas C Cullen, Shorena Janelidze, Erik Stomrud, et al.
Med (New York, N.Y.)|September 10, 2024
Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's diseaseYan Hu, Min Cho, Pallavi Sachdev, et al.
Alzheimer'S Research & Therapy|March 19, 2020
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identificationNicolas R Barthélemy, Randall J Bateman, Christophe Hirtz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersPetrice M Cogswell, Gregory M Preboske, Gregory Klein, et al.
Pageof 40